Endocrine and neuroendocrine tumours
- Lenvatinib Provides Encouraging Responses in Advanced or Metastatic Thymic Carcinoma
- LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer
- Thyroid cancer: ESMO Clinical Practice Guidelines
- eUpdate: Hepatocellular Carcinoma Treatment Recommendations
- eUpdate: Hepatocellular Carcinoma Algorithms
- Molecular Characterisation of Non-functional Pancreatic Neuroendocrine Tumours
- BLU-667 in RET-driven NSCLC and Thyroid Cancer
- ESMO Preceptorship on Gastroenteropancreatic Neuroendocrine Neoplasms 2019: Prague
- eUpdate – Hepatocellular Carcinoma Treatment Recommendations
- NICE Issues Evidence-Based Recommendations on Lenvatinib and Sorafenib for Treatment of Differentiated Thyroid Cancer
- NICE Issues Evidence-Based Recommendations for Lutetium (177Lu) Oxodotreotide for Treating GEP NETs
- FDA Approves Iobenguane I 131 for Pheochromocytoma or Paraganglioma
- EMA Recommends Extension of Indications for Lenvatinib
- FDA Approves Dabrafenib Plus Trametinib for Anaplastic Thyroid Cancer with BRAF V600E Mutation
- eUpdate – Medullary Thyroid Cancer Treatment Recommendations
- FDA Approves Lutetium Lu 177 Dotatate for Treatment of GEP NETs
- ESMO 2017: Immune Landscape of PanNETs
- ESMO 2017: Improved Survival Demonstrated with NSCLC-chemotherapy in Pulmonary Large Cell Neuroendocrine Carcinoma with RB1 Wild-type
- ESMO 2017: First KEYNOTE-028 Report of Pembrolizumab Activity in Patients with PD-L1-positive pNETs and Carcinoid Tumours
- ESMO 2017: Subtypes of Thymic Carcinomas Show Different Genomic Alterations and Tumour Mutational Burden
- EMA Recommends Granting a Marketing Authorisation for Telotristat Ethyl
- EMA Recommends Granting a Marketing Authorisation for Lutetium (177Lu) Oxodotreotide
- FDA Approves Telotristat Ethyl for Carcinoid Syndrome Diarrhoea
- Nature Reviews Clinical Oncology – Year in Review
- EMA Recommends Extension of Therapeutic Indications for Vandetanib